Pharmacological treatment of depression in people with a primary brain tumour.

The Cochrane Database of Systematic Reviews
Zachary BeeversAlasdair G Rooney

Abstract

This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear. To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour. We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019). We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour. No st...Continue Reading

References

Mar 1, 1985·Journal of Neurology, Neurosurgery, and Psychiatry·J M Rabey, E Avrahami
Jun 1, 1983·Acta Psychiatrica Scandinavica·A S Zigmond, R P Snaith
Jan 1, 1981·The American Journal of Psychiatry·L K Oyewumi, Y D Lapierre
Dec 1, 1996·Journal of Personality Assessment·A T BeckW Ranieri
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A MeyersV A Levin
May 5, 2000·The Cochrane Database of Systematic Reviews·M S Lima, J Moncrieff
Oct 6, 2000·Acta Psychiatrica Scandinavica. Supplementum·S PerettiI Hindmarch
Oct 18, 2000·The Cochrane Database of Systematic Reviews·M S Lima, J Moncrieff
Jan 24, 2002·Therapeutic Drug Monitoring·Houda HachadRene H Levy
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary R MorrowUNKNOWN University of Rochester Cancer Center Community Clinical Oncology Program
Jan 9, 2004·Journal of Pain and Symptom Management·Kevin D SteinChristina Thors
Jan 28, 2004·Neurosurgery·N Scott LitofskyUNKNOWN Glioma Outcomes Project Investigators
Feb 20, 2004·The Cochrane Database of Systematic Reviews·J MoncrieffR Hardy
May 15, 2004·Current Psychiatry Reports·Dan V IosifescuMaurizio Fava
May 19, 2004·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Paolo Cassano, Maurizio Fava
Sep 6, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Arja MainioPirkko Räsänen
Oct 20, 2005·The Cochrane Database of Systematic Reviews·J WijkstraW A Nolen
Nov 18, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Doron GothelfIsaac Yaniv
Dec 15, 2005·International Journal of Clinical Practice·S A Montgomery
Jan 27, 2006·The Cochrane Database of Systematic Reviews·P MottramJ Strobl
Mar 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward G ShawStephen R Rapp
Sep 9, 2006·European Archives of Psychiatry and Clinical Neuroscience·Arja MainioPirkko Räsänen
Dec 5, 2006·Current Opinion in Psychiatry·Zoltán Rihmer
Jul 12, 2007·Journal of Occupational and Environmental Medicine·Michael FeuersteinJonne G Ronquillo
Aug 2, 2008·The New England Journal of Medicine·Patrick Y Wen, Santosh Kesari
Sep 13, 2008·Surgical Neurology·Muraya GathinjiAlfredo Quinones-Hinojosa
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Maree L HackettJun Xia
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susanne O DaltonChristoffer Johansen
Mar 6, 2009·Journal of Neuro-oncology·N Scott Litofsky, Andrew G Resnick
May 7, 2009·Journal of Palliative Medicine·Leslie BlackhallElena Farace
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Alasdair Rooney, Robert Grant
Aug 14, 2010·Current Opinion in Oncology·Roberta RudàRiccardo Soffietti
Sep 8, 2010·Journal of Neuro-oncology·Joseph WiemelsElizabeth B Claus
Apr 23, 2011·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Mariana R GazzottiMilena Vidotto
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alasdair G RooneyRobin Grant

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved